Bundibugyo Virus

• The Bundibugyo virus, a rare orthoebolavirus, remains a significant public health threat due to its ability to cause severe epidemic disease with high mortality rates. • While advances in supportive care have improved patient outcomes, there are currently no licensed vaccines or approved therapeutics specifically designed for the Bundibugyo virus. • Research using human serum and nonhuman primates indicates that vaccines developed for the Ebola virus may provide critical cross-protection against this related pathogen.

• In May 2026, outbreaks of Bundibugyo virus disease (BVD) were reported in Uganda and the Ituri province of the Democratic Republic of the Congo. • A transmission model was used to project the growth of the outbreak over a three-month period, highlighting the risk of rapid escalation. • The situation is critical because there are currently no approved vaccines or medications available to treat the *Orthoebolavirus bundibugyoense* species.

• A new outbreak of the Ebola Bundibugyo virus has emerged, affecting the Democratic Republic of Congo, Uganda, and surrounding neighboring countries. • Pharmaceutical and biotech companies are collaborating with global health and humanitarian partners to coordinate a rapid medical response. • This industry involvement is critical to accelerating the containment of the virus and providing necessary treatments to affected populations.